moderate - Revenue is partially insulated by long research cycles and multi-year grant funding, but discretionary capital equipment purchases by academic labs and biotech companies decline during economic downturns. Biopharma R&D spending tends to be more resilient than broader economy, but early-stage biotech funding (venture capital, IPOs) is highly cyclical and impacts customer budgets. Approximately 30-40% of revenue comes from biopharma which is less cyclical than academic/government customers.

Rising interest rates negatively impact 10x Genomics through multiple channels: (1) biotech venture funding contracts sharply in high-rate environments, reducing customer budgets for genomics tools, (2) academic endowment returns compress, constraining research spending, (3) valuation multiples for unprofitable growth companies contract as discount rates rise. The company's own financing costs are minimal given low debt levels, but customer financing constraints are material. The 2022-2023 biotech funding drought directly impacted instrument sales.

growth - Investors are betting on long-term market expansion in spatial biology and single-cell genomics becoming standard research tools, accepting near-term losses for potential market leadership. The 54% one-year return and strong recent momentum attracts growth and momentum investors. Negative earnings and high P/S ratio (3.7x) exclude value investors. No dividend, purely capital appreciation thesis.